| Filed On | Filing |
|---|---|
| 01 Jun 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Updated Executive Retirement and Strategic Consulting Agreement |
| 13 May 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Following up on discussions yesterday, this letter confirms the ending of your employment with Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigned, hereafter “Moderna” or the “Company... |
| 09 Jun 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with the appointment of David W. Meline as Chief Financial Officer of the Company, effective June 8, 2020, Mr. Meline was designated as the Company’s principal financial officer and principal accounting officer, succeeding ... |
| 09 May 2019 |
8-K/A: Results of Operations and Financial Condition
Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline |
Loading...